Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Denali Therapeutics Inc., Neurocrine Biosciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Denali Therapeutics Inc., Neurocrine Biosciences and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Denali Therapeutics Inc., Neurocrine Biosciences and Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Latest Biotechnology and Denali Therapeutics Inc., Neurocrine Biosciences, Inc. Stock News

As of June 29, 2026, Denali Therapeutics Inc. had a $4.1 billion market capitalization, compared to the Biotechnology median of $291.1 million. Denali Therapeutics Inc.’s stock is up 55.8% in 2026, up 3.8% in the previous five trading days and up 78.67% in the past year.

Currently, Denali Therapeutics Inc. does not have a price-earnings ratio. Denali Therapeutics Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of June 29, 2026, Denali Therapeutics Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-2.315 per share for the current fiscal year. Denali Therapeutics Inc. does not currently pay a dividend.

As of June 29, 2026, Neurocrine Biosciences, Inc. had a $17.1 billion market cap, putting it in the 84th percentile of all stocks. Neurocrine Biosciences, Inc.’s stock is up 18.8% in 2026, up 4.4% in the previous five trading days and up 34.17% in the past year.

Currently, Neurocrine Biosciences, Inc.’s price-earnings ratio is 26.1. Neurocrine Biosciences, Inc.’s trailing 12-month revenue is $3.1 billion with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was 42.2%. Analysts expect adjusted earnings to reach $10.184 per share for the current fiscal year. Neurocrine Biosciences, Inc. does not currently pay a dividend.

How We Compare Denali Therapeutics Inc., Neurocrine Biosciences and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Denali Therapeutics Inc., Neurocrine Biosciences and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Denali Therapeutics Inc., Neurocrine Biosciences and Inc. Growth Grades

Company	Ticker	Growth
Denali Therapeutics Inc.	DNLI	na
Neurocrine Biosciences, Inc.	NBIX	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Denali Therapeutics Inc. does not have a meaningful Growth Score. Neurocrine Biosciences, Inc. has a Growth Score of 69, which is Strong.

The Growth Stock Winner: Undetermined

If you are strictly a growth investor, you may want to add Neurocrine Biosciences, Inc. to your watch list. However, because only one of the companies in this comparison has a valid Growth Grade, we cannot call it a clear winner. Evaluation of the other grades for both companies is necessary in order to understand which stock is the better investment based on AAII’s proprietary scores and analysis.

Denali Therapeutics Inc., Neurocrine Biosciences and Inc.’s Momentum Grades

Company	Ticker	Momentum
Denali Therapeutics Inc.	DNLI	A
Neurocrine Biosciences, Inc.	NBIX	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Denali Therapeutics Inc. has a Momentum Score of 84, which is Very Strong. Neurocrine Biosciences, Inc. has a Momentum Score of 71, which is Strong.

The Momentum Grade Winner: Denali Therapeutics Inc.

As you can clearly see from the Momentum Grade breakdown above, Denali Therapeutics Inc. is considered to have stronger momentum compared to Neurocrine Biosciences, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Denali Therapeutics Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Denali Therapeutics Inc., Neurocrine Biosciences and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Denali Therapeutics Inc.	DNLI	C
Neurocrine Biosciences, Inc.	NBIX	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Denali Therapeutics Inc. has a Earnings Estimate Score of 56, which is Neutral. Neurocrine Biosciences, Inc. has a Earnings Estimate Score of 40, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Denali Therapeutics Inc., Neurocrine Biosciences or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Denali Therapeutics Inc., Neurocrine Biosciences or Inc. is the better investment when it comes to estimate revisions.

Other Denali Therapeutics Inc., Neurocrine Biosciences and Inc. Grades

In addition to Growth, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Denali Therapeutics Inc., Neurocrine Biosciences and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Denali Therapeutics Inc., Neurocrine Biosciences or Inc. Stock?

Overall, Denali Therapeutics Inc. stock has a Growth Score of , Momentum Score of 84 and Estimate Revisions Score of 56.

Neurocrine Biosciences, Inc. stock has a Growth Score of 69, Momentum Score of 71 and Estimate Revisions Score of 40.

Comparing Denali Therapeutics Inc., Neurocrine Biosciences and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.